Discounted Cash Flow (DCF) Analysis Levered

ReShape Lifesciences Inc. (RSLS)

$0.3003

-0.00 (-0.36%)
All numbers are in Millions, Currency in USD
Stock DCF: -2,966,001.70 | 0.3003 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.290.6115.0911.3013.6092.80633.224,320.7829,482.86201,176.49
Revenue (%)
Operating Cash Flow -24.59-27.49-14.20-8.55-15.38-1,247.99-8,515.70-58,106.94-396,493.14-2,705,473.85
Operating Cash Flow (%)
Capital Expenditure -0.14-0.05-0.01-0.39-0.35-4.63-31.61-215.67-1,471.64-10,041.77
Capital Expenditure (%)
Free Cash Flow -24.73-27.54-14.21-8.94-15.73-1,252.63-8,547.31-58,322.61-397,964.78-2,715,515.62

Weighted Average Cost Of Capital

Share price $ 0.3,003
Beta 1.500
Diluted Shares Outstanding 6.93
Cost of Debt
Tax Rate 0.17
After-tax Cost of Debt 4.99%
Risk-Free Rate
Market Risk Premium
Cost of Equity 10.885
Total Debt -
Total Equity 2.08
Total Capital 2.08
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.290.6115.0911.3013.6092.80633.224,320.7829,482.86201,176.49
Operating Cash Flow -24.59-27.49-14.20-8.55-15.38-1,247.99-8,515.70-58,106.94-396,493.14-2,705,473.85
Capital Expenditure -0.14-0.05-0.01-0.39-0.35-4.63-31.61-215.67-1,471.64-10,041.77
Free Cash Flow -24.73-27.54-14.21-8.94-15.73-1,252.63-8,547.31-58,322.61-397,964.78-2,715,515.62
WACC
PV LFCF -1,129.71-6,952.21-42,783.60-263,288.43-1,620,265.63
SUM PV LFCF -1,934,419.58

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 10.88
Free cash flow (t + 1) -2,769,825.94
Terminal Value -31,191,733.51
Present Value of Terminal Value -18,611,159.26

Intrinsic Value

Enterprise Value -20,545,578.84
Net Debt -22.77
Equity Value -20,545,556.07
Shares Outstanding 6.93
Equity Value Per Share -2,966,001.70